Abstract
Background SARS-CoV-2 infections of infants and toddlers are usually mild but can result in life-threatening disease. SARS-CoV-2 RNA been detected in the breast milk of lactating women, but the potential role of breastfeeding in transmission to infants has remained uncertain.
Methods Breast milk specimens were examined for the presence of the virus by RT-PCR and/or culture. Specimens that contained viral RNA (vRNA) were examined for the presence of subgenomic coronavirus RNA (sgRNA), a putative marker of infectivity. Culture methods were used to determine the thermal stability of SARS-CoV-2 in human milk.
Results Breast milk samples from 110 women (65 confirmed with a SARS-CoV-2 diagnostic test, 36 with symptoms but without tests, and 9 with symptoms but a negative SARS-CoV-2 diagnostic test) were tested by RT-PCR (285 samples) and/or viral culture (160 samples). Although vRNA of SARS-CoV-2 was detected in the milk of 7 of 110 (6%) women with either a confirmed infection or symptomatic illness, and in 6 of 65 (9%) of women with a positive SARS-CoV-2 diagnostic test, virus was not detected in any culture. None of the 7 milk specimens with detectable vRNA contained sgRNA. Notably, when artificially added to human milk in control experiments, infectious SARS-CoV-2 could be cultured despite several freeze-thaw cycles, as occurs in the storage and usage of human milk.
Conclusions SARS-CoV-2 RNA can be found infrequently in the breastmilk of women with recent infection, but we found no evidence that breastmilk contains infectious virus or that breastfeeding represents a risk factor for transmission of infection to infants.
Question SARS-CoV-2 RNA has been detected in a small number of human milk samples collected from recently infected women. The role of breastfeeding in transmission of the virus to infants has remained uncertain due to the small number of specimens analyzed in any study published thus far.
Findings In a total study group of 110 women, SARS-CoV-2 RNA was detected in milk from 6 of 65 women (9.2%) with recent confirmed infection. Neither infectious virus nor subgenomic RNA (a marker of virus infectivity) were detected in any of the samples.
Meaning We found no evidence that infectious SARS-CoV-2 is present milk from recently infected women, even if SARS-CoV-2 PCR tests are positive, providing reassurance of the safety of breastfeeding.
Competing Interest Statement
Conflict of Interest Disclosures Dr Bode reported serving as the UC San Diego Chair of Collaborative Human Milk Research, which is endowed by the Family Larsson-Rosenquist Foundation. Medela Corporation provided milk sample collection materials for this study. Dr. Chambers reports that shipping of milk samples was financially supported by the Mothers' Milk Bank at Austin, an accredited milk bank and member of the Human Milk Banking Association of North America. The other authors have no relevant conflicts to disclose.
Funding Statement
Paul Krogstad received supported from the University of California Los Angeles (UCLA) AIDS Institute, UCLA CFAR (AI028697), the James B. Pendleton Charitable Trust, and the McCarthy Family Foundation. Christina Chambers received an award for this study from the University of California Office of the President Emergency COVID-19 Research Program, and also received resources for the Human Milk Research Biorepository from the Altman Clinical Translational Research Institute (ACTRI) at UC San Diego funded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) under Award Number UL1TR001442. Lars Bode is the UC San Diego Chair of Collaborative Human Milk Research, endowed by the Family Larsson-Rosenquist Foundation that also provided an unrestricted COVID19 emergency gift fund. Grace Aldrovandi is supported by the IMPAACT Network. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Role of Funder/Sponsor: The funders and sponsors of this study did not participate in the work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of California San Diego institutional review board and all participating women provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosures Dr Bode reported serving as the UC San Diego Chair of Collaborative Human Milk Research, which is endowed by the Family Larsson-Rosenquist Foundation. Medela Corporation provided milk sample collection materials for this study. Dr. Chambers reports that shipping of milk samples was financially supported by the Mothers’ Milk Bank at Austin, an accredited milk bank and member of the Human Milk Banking Association of North America. The other authors have no relevant conflicts to disclose.
Funding/Support Paul Krogstad received supported from the University of California Los Angeles (UCLA) AIDS Institute, UCLA CFAR (AI028697), the James B. Pendleton Charitable Trust, and the McCarthy Family Foundation. Christina Chambers received an award for this study from the University of California Office of the President Emergency COVID-19 Research Program, and also received resources for the Human Milk Research Biorepository from the Altman Clinical Translational Research Institute (ACTRI) at UC San Diego funded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) under Award Number UL1TR001442.
Lars Bode is the UC San Diego Chair of Collaborative Human Milk Research, endowed by the Family Larsson-Rosenquist Foundation that also provided an unrestricted COVID19 emergency gift fund. Grace Aldrovandi is supported by the IMPAACT Network. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716(IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Role of Funder/Sponsor: The funders and sponsors of this study did not participate in the work.
Drs. Aldrovandi and Bode were leaders in the design of the study and all aspects of data review, provided financial support, and were integrally involved in manuscript finalization
Dr. Chambers and Ms. Bertrand participated in study design, supervised the collection of specimens used in the study, performed demographic and statistical analysis, and were involved in preparing the manuscript.
Dr. Contreras was involved in study design, devised and optimized the breast milk quantitative RT-PCR assay, and performed most of the quantitative PCR studies.
Ms. Ng prepared the virus stocks used in key experiments and performed breast milk viral cultures under Biosafety level 3 conditions, drafted portions of the method section, and
Dr. Tobin aided in designing the study, supervised study organization and sample sharing, performed quantitative RT-PCR assays, and was involved in editing the final manuscript.
All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Data Availability
Data access may be provided, with appropriate ethics approval, by contacting the authors.
Abbreviations
- SARS-CoV-2
- Severe acute respiratory syndrome associated coronavirus type 2
- MIS-C
- Multisystem inflammatory syndrome in children
- TCID50
- Median Tissue culture infectious dose
- Vero-E6 cells
- Cercopithecus aethiops–derived epithelial kidney cells
- sgRNA
- subgenomic RNA
- ECMO
- Extracorporeal membrane oxygenation
